Cancer Research and Treatment

Original Articles

Breast cancer

A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03): Dae-Won Lee, Bhumsuk Keam, Keun Seok Lee, Jin-Hee Ahn, Joohyuk Sohn, Jin Seok Ahn, Moon Hee Lee, Jee Hyun Kim, Kyung Eun Lee, Hyo Jung Kim, Si-Young Kim, Yeon Hee Park, Chan-Young Ock, Kyung-Hun Lee, Sae-Won Han, Sung-Bae Kim, Young Hyuck Im, Hyun Cheol Chung, Do-Youn Oh, Seock-Ah Im; Cancer Res Treat. 2023;55(2):523-530. Published online November 8, 2022; DOI: https://doi.org/10.4143/crt.2022.1360

Purpose
This single-arm phase II trial investigate the efficacy and safety of S-1 plus oxaliplatin (SOX) in patients with metastatic breast cancer.
Materials and Methods
Patients with metastatic breast cancer previously treated with anthracyclines and taxanes were enrolled. Patients received S-1 (40-60 mg depending on patient’s body surface area, twice a day, day 1-14) and oxaliplatin (130 mg/m2, day 1) in 3 weeks cycle until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumor 1.1. Secondary endpoints included time-to-progression (TTP), duration-of-response (DoR), overall survival (OS), and adverse events.
Results
A total of 87 patients were enrolled from 11 institutions in Korea. Hormone receptor was positive in 54 (62.1%) patients and six (6.9%) had human epidermal growth factor receptor 2–positive disease. Forty-eight patients (85.1%) had visceral metastasis and 74 (55.2%) had more than three sites of metastases. The ORR of SOX regimen was 38.5% (95% confidence interval [CI], 26.9 to 50.0) with a median TTP of 6.0 months (95% CI, 5.1 to 6.9). Median DoR and OS were 10.3 months (95% CI, 5.5 to 15.1) and 19.4 (95% CI, not estimated) months, respectively. Grade 3 or 4 neutropenia was reported in 28 patients (32.1%) and thrombocytopenia was observed in 23 patients (26.6%).
Conclusion
This phase II study showed that SOX regimen is a reasonable option in metastatic breast cancer previously treated with anthracyclines and taxanes.

Citations

Citations to this article as recorded by

Unraveling the immune landscape and therapeutic biomarker PMEPA1 for oxaliplatin resistance in colorectal cancer: A comprehensive approach
Zhengguang Zhang, Tianming Lu, Zhe Zhang, Zixian Liu, Ruoning Qian, Ruogu Qi, Fuqiong Zhou, Min Li
Biochemical Pharmacology.2024; 222: 116117. CrossRef
Efficacy and safety of utidelone plus capecitabine in advanced first-line therapy for metastatic breast cancer: A multicenter real-world study
Pingping Bi, Xi Wang, Rui Liu, Xiuqin Li, Shanrong Wei, Jiawen Zhao, Xin Tan, Fan Zhang, Qing Mao, Ying Zhang, Baoyan Tang, Xueqiong Xun, Rong Guo, Kai Zheng, Shaoqiang Zhou, Shicong Tang
Surgery Open Science.2023; 16: 171. CrossRef

4,676 View
168 Download
2 Web of Science
2 Crossref

Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type: Hyun Jee Kim, Chan-Young Ock, Tae Min Kim, Sung Hee Lee, Ju-Yeun Lee, Sun hoi Jung, Yoon Sook Cho, Miso Kim, Bhumsuk Keam, Dong-Wan Kim, Il Han Kim, Dae Seog Heo; Cancer Res Treat. 2018;50(3):670-680. Published online July 3, 2017; DOI: https://doi.org/10.4143/crt.2017.051

Abstract PDF Supplementary Material PubReader ePub

Purpose
The aim of this study was to compare asparaginase-related toxicities in two asparaginase preparations, namely native Escherichia coli L-asparaginase (L-ASP) and pegylated asparaginase (PEG-ASP) in combination with ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) in natural killer (NK)/T-cell lymphoma (NTCL).
Materials and Methods
A total of 41 NTCL patients who received IMEP plus native E. coli L-ASP or PEG-ASP at Seoul National University Hospital were included in this study between January 2013 and March 2016. IMEP/ASP treatment consisted of ifosfamide, methotrexate, etoposide, plus native E. coli L-ASP (6,000 IU/m² on days 1, 3, 5, 7, 9, and 11) or PEG-ASP (2,500 IU/m² on day 1) every 3 weeks. ASP-related toxicities, toxicity patterns, length of hospital stay, and clinical outcomes were compared between the different treatment groups.
Results
The frequency of ASP-related toxicities was similar between the IMEP plus native E. coli L-ASP group and the PEG-ASP group apart from hypofibrinogenemia (native E. coli L-ASP vs. PEG-ASP group, 86.4% vs. 36.8%; p=0.001). Although post-treatment transaminase and albumin levels were significantly high and low, respectively, hepatotoxicity gradients before and after treatment did not differ significantly between the groups. Since PEG-ASP was given at an outpatient clinic in some patients, length of hospital stay was significantly shorter in the IMEP plus PEG-ASP group (median, 4.0 vs. 6.0 days; p=0.002). A favorable tendency of clinical outcomes was observed in NTCL patients treated with IMEP plus PEG-ASP (complete remission rate, 73.7% vs. 45.5%; p=0.067).
Conclusion
IMEP plus PEG-ASP showed similar ASP-related toxicities, shorter length of hospital stay, and a trend towards improved clinical outcomes compared with IMEP plus native E. coli L-ASP in NTCL.

Citations

Citations to this article as recorded by

From the midfacial destructive drama to the unfolding EBV story: a short history of EBV-positive NK-cell and T-cell lymphoproliferative diseases
Chi Sing Ng
Pathology.2024; 56(6): 773. CrossRef
Treatment of extranodal NK/T-cell lymphoma: From past to future
Zheng Yan, Shuna Yao, Zhizhong Wang, Wenping Zhou, Zhihua Yao, Yanyan Liu
Frontiers in Immunology.2023;[Epub] CrossRef
Efficacy of a short sandwich protocol, methotrexate, gemcitabine, L‐asparaginase and dexamethasone chemotherapy combined with radiotherapy, in localised newly diagnosed NK/T‐cell lymphoma: A French retrospective study
Sammara Chaubard, Amira Marouf, David Lavergne, François Lemonnier, Julien Rossignol, Aline Clavert, Rémy Gressin, Guillaume Cartron, Agathe Waultier‐Rascalou, Jacques Vargaftig, Gilles Salles, Emmanuel Bachy, Hervé Ghesquières, Olivier Tournilhac, Adrien
British Journal of Haematology.2023; 201(4): 673. CrossRef
Is PEGylation of Drugs Associated with Hypersensitivity Reactions? An Analysis of the Italian National Spontaneous Adverse Drug Reaction Reporting System
Salvatore Crisafulli, Paola Maria Cutroneo, Nicoletta Luxi, Andrea Fontana, Carmen Ferrajolo, Pasquale Marchione, Laura Sottosanti, Giovanna Zanoni, Ugo Moretti, Silvia Franzè, Paola Minghetti, Gianluca Trifirò
Drug Safety.2023; 46(4): 343. CrossRef
Incidence and Related Factors of L-asparaginase-induced Hypersensitivity Reactions Requiring Treatment Changes in Pediatric Patients with Acute Lymphoblastic Leukemia
Eun Eui Noh, Yujin Lee, Sukmin Hong, Sung Hwan Kim, Sung Yun Suh, Yoon Sook Cho, Hyun Jin Park, Bo Kyung Kim, Kyung Taek Hong, Jung Yoon Choi, Hyoung Jin Kang, Ju-Yeun Lee
Journal of Korean Society of Health-System Pharmacists.2023; 40(2): 171. CrossRef
DDGP followed by radiotherapy vs VIPD followed by radiotherapy in newly diagnosed early NK/T-cell lymphoma
Lei Zhang, Chenxing Shangguan, Xin Li, Ling Li, Xinhua Wang, Xiaorui Fu, Zhenchang Sun, Yonggang Shi, Jingjing Wu, Xudong Zhang, Hui Yu, Feifei Nan, Jiaqin Yan, Yu Chang, Zhiyuan Zhou, Xiaolong Wu, Xiaoyan Feng, Xiyang Liu, Hongwei Xue, Liqun Zou, Yi Lu,
Leukemia Research.2022; 118: 106881. CrossRef
DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T‐cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients
Xin Wang, Junxia Hu, Meng Dong, Mengjie Ding, Linan Zhu, Jingjing Wu, Zhenchang Sun, Xin Li, Lei Zhang, Ling Li, Xinhua Wang, Xiaorui Fu, Guannan Wang, Qingjiang Chen, Mingzhi Zhang, Xudong Zhang
Clinical and Translational Science.2021; 14(1): 405. CrossRef
Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge
Yiwei Liu, Colton A. Smith, John C. Panetta, Wenjian Yang, Lauren E. Thompson, Jacob P. Counts, Alejandro R. Molinelli, Deqing Pei, Nancy M. Kornegay, Kristine R. Crews, Hope Swanson, Cheng Cheng, Seth E. Karol, William E. Evans, Hiroto Inaba, Ching-Hon P
Journal of Clinical Oncology.2019; 37(23): 2051. CrossRef
Multiple drugs

Reactions Weekly.2018; 1717(1): 197. CrossRef
PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity
Wen Zheng, Yuhuan Gao, Xiaoyan Ke, Weijing Zhang, Liping Su, Hanyun Ren, Ningjing Lin, Yan Xie, Meifeng Tu, Weiping Liu, Lingyan Ping, Zhitao Ying, Chen Zhang, Lijuan Deng, Xiaopei Wang, Yuqin Song, Jun Zhu
BMC Cancer.2018;[Epub] CrossRef

11,984 View
390 Download
8 Web of Science
10 Crossref

The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis: Ryul Kim, Seokyung Hahn, Junghoon Shin, Chan-Young Ock, Miso Kim, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo; Cancer Res Treat. 2016;48(3):907-916. Published online November 17, 2015; DOI: https://doi.org/10.4143/crt.2015.359

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to compare the survival of patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) undergoing concurrent chemoradiotherapy (CRT) alone with that of patients undergoing induction chemotherapy (IC) using docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by CRT.
Materials and Methods
A search of the PubMed, EMBASE, and Cochrane Library databases was performed in April 2015 and abstracts from the American Society of Clinical Oncology meetings (2008-2014) were reviewed. Summaries of the results were pooled using a fixed-effect model, and the risk of bias was evaluated using the Cochrane tool.
Results
A total of six relevant trials comprising 1,280 patients were identified. There was no statistically significant overall survival (OS) advantage for TPF prior to CRT (TPF/CRT) over CRT alone (hazard ratio [HR] 0.92; 95% confidence interval [CI], 0.79 to 1.09; p=0.339). Progression- free survival (PFS) was significantly longer in the TPF/CRT arms (HR, 0.82; 95% CI, 0.70 to 0.95; p=0.009). Patients with non-oropharyngeal LA-HNSCC obtained the greatest OS and PFS benefits from TPF (HR, 0.68; 95% CI, 0.47 to 0.99; p=0.043 and HR, 0.67; 95% CI, 0.48 to 0.94; p=0.022, respectively). The complete response rate was significantly increased (risk ratio [RR], 1.34; 95% CI, 1.14 to 1.56; p < 0.001), and the distant metastasis rate tended to decrease (RR, 0.65; 95% CI, 0.40 to 1.04; p=0.071) in the TPF/CRT arms.
Conclusion
IC with TPF followed by CRT is not superior to CRT alone for OS. However, PFS and the complete response rate were significantly improved in the TPF/CRT arms. TPF/CRT for patients with nonoropharyngeal LA-HNSCC provided clear survival advantages.

Citations

Citations to this article as recorded by

Role of induction chemotherapy for locally advanced oral squamous cell carcinoma. A systematic review and meta-analysis based on the GRADE approach
Saisei Fu, Haruki Sato, Mitsuo Goto, Saki Tanno, Daisuke Takeda, Taiki Suzuki, Hidemichi Yuasa, Masatoshi Adachi, Narikazu Uzawa, Hiroshi Kurita
Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology.2024; 36(3): 278. CrossRef
Clinical decision pathway and management of locally advanced head and neck squamous cell carcinoma: A multidisciplinary consensus in Asia-Pacific
Ye Guo, Torahiko Nakashima, Byoung Chul Cho, Darren W.-T. Lim, Muh-Hwa Yang, Pei-Jen Lou, June Corry, Jin Ching Lin, Guo Pei Zhu, Kyung Hwan Kim, Bin Zhang, Zhiming Li, Ruey-Long Hong, Junice Yi Siu Ng, Ee Min Tan, Yan Ping Liu, Con Stylianou, Carmel Spit
Oral Oncology.2024; 148: 106657. CrossRef
International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors
Edward C. Kuan, Eric W. Wang, Nithin D. Adappa, Daniel M. Beswick, Nyall R. London, Shirley Y. Su, Marilene B. Wang, Waleed M. Abuzeid, Borislav Alexiev, Jeremiah A. Alt, Paolo Antognoni, Michelle Alonso‐Basanta, Pete S. Batra, Mihir Bhayani, Diana Bell,
International Forum of Allergy & Rhinology.2024; 14(2): 149. CrossRef
Indian clinical practice consensus guidelines for the management of oropharyngeal cancer: Update 2022
Vanita Noronha, Kumar Prabhash, K Govind Babu, Pankaj Chaturvedi, Moni Kuriakose, Praveen Birur, Anil K Anand, Ashish Kaushal, Abhishek Mahajan, Judita Syiemlieh, Manish Singhal, Munish Gairola, Prakash Ramachandra, Sumit Goyal, Subashini John, Rohit Nayy
Cancer Research, Statistics, and Treatment.2024; 7(Suppl 1): S12. CrossRef
Indian clinical practice consensus guidelines for the management of hypopharyngeal cancer: Update 2022
K Govind Babu, Kumar Prabhash, Pankaj Chaturvedi, Moni Kuriakose, Praveen Birur, Anil K. Anand, Ashish Kaushal, Abhishek Mahajan, Judita Syiemlieh, Manish Singhal, Munish Gairola, Prakash Ramachandra, Sumit Goyal, Subashini John, Rohit Nayyar, Vijay M. Pa
Cancer Research, Statistics, and Treatment.2024; 7(Suppl 1): S17. CrossRef
Locally advanced and unresectable squamous cell carcinoma
Julio José Lambea Sorrosal, María Zapata García, Alba Moratiel Pellitero, Karla Andrea Osorio Macassi, Isabel Pajares Bernad, Inés Ruiz Moreno, Sara Esteras Per
Revisiones en Cáncer.2024;[Epub] CrossRef
Role of induction chemotherapy in advanced‐stage olfactory neuroblastoma
Sung‐Woo Cho, Bhumsuk Keam, Keun‐Wook Lee, Ji‐Won Kim, Doo Hee Han, Hyun Jik Kim, Jeong‐Whun Kim, Dong‐Young Kim, Chae‐Seo Rhee, Yun Jung Bae, Ji‐Hoon Kim, Keun‐Yong Eom, Hong‐Gyun Wu, Yong Hwy Kim, Chae‐Yong Kim, Sun Ha Paek, Hyojin Kim, Tae‐Bin Won
International Forum of Allergy & Rhinology.2024; 14(12): 1882. CrossRef
Neoadjuvant Capecitabine in Operable HPV‐Negative Head and Neck Cancer: Fortuitous Findings in a Resource Constrained Setting
Marco A. Mascarella, Keith Richardson, Alex Mlynarek, Michael P. Hier, Derin Caglar, Livia Florianova, Marc Philippe Pusztaszeri, Khalil Sultanem, Nader Sadeghi, Nathaniel Bouganim, Khashayar Esfahani
Otolaryngology–Head and Neck Surgery.2024; 171(6): 1773. CrossRef
Outcomes of Neoadjuvant Chemotherapy in Locally Advanced Oral Cancers: A Retrospective Analytical Study
Monesha Baskaran, S.M. Azeem Mohiyuddin, G. N. Manjunath, A. Sagayaraj, M. Kouser, Ravindra P Deo, Anil K Sakalecha, Kalyani Raju, Sampath Kumar M.N.
Cureus.2024;[Epub] CrossRef
Indian clinical practice consensus guidelines for the management of oropharyngeal cancer - Update 2023
Vanita Noronha, K Govind Babu, HS Darling, Pankaj Chaturvedi, Moni Kuriakose, Praveen Birur, Ashish Kaushal, Abhishek Mahajan, Manish Singhal, Munish Gairola, Sumit Goyal, Vijay M Patil, Vishal Rao, Goura K. Rath, Prabhash Kumar
Cancer Research, Statistics, and Treatment.2024; 7(Suppl 2): S54. CrossRef
Suppression of TLR signaling by IRAK-1 and -4 dual inhibitor decreases TPF-resistance-induced pro-oncogenic effects in HNSCC
Humayara Khan, Sachchida Nand Pandey, Abhishek Mishra, Ratika Srivastava
3 Biotech.2023;[Epub] CrossRef
Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
Shuwen Zheng, Yumei Feng, Chan Li, Jie Zhang, Ke Xie
Oncology and Therapy.2023; 11(2): 185. CrossRef
Induction chemotherapy in locally advanced head and neck cancers, is there a best choice?
Hoda Mahdavi
Critical Reviews in Oncology/Hematology.2023; 186: 103986. CrossRef
Protective Effect of Electroacupuncture on Chemotherapy-Induced Salivary Gland Hypofunction in a Mouse Model
Thanh-Hien Vu Nguyen, Kuo-Chou Chiu, Yin-Hwa Shih, Chung-Ji Liu, Tran Van Bao Quach, Shih-Min Hsia, Yi-Hung Chen, Tzong-Ming Shieh
International Journal of Molecular Sciences.2023; 24(14): 11654. CrossRef
Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01)
Yun-Gyoo Lee, Eun Joo Kang, Bhumsuk Keam, Jin-Hyuk Choi, Jin-Soo Kim, Keon Uk Park, Kyoung Eun Lee, Hyo Jung Kim, Keun-Wook Lee, Min Kyoung Kim, Hee Kyung Ahn, Seong Hoon Shin, Hye Ryun Kim, Sung-Bae Kim, Hwan Jung Yun
Cancer Research and Treatment.2022; 54(1): 109. CrossRef
The role of induction chemotherapy in patients with locally advanced head and neck squamous cell carcinoma: A nationwide population-based matched study
Meng-Che Hsieh, Chih-Chun Wang, Chuan-Chien Yang, Ching-Feng Lien, Chien-Chung Wang, Yu-Chen Shih, Shyh-An Yeh, Tzer-Zen Hwang
Oral Oncology.2022; 128: 105848. CrossRef
SEOM clinical guidelines for the treatment of head and neck cancer (2020)
R. Mesia, L. Iglesias, J. Lambea, J. Martínez-Trufero, A. Soria, M. Taberna, J. Trigo, M. Chaves, A. García-Castaño, J. Cruz
Clinical and Translational Oncology.2021; 23(5): 913. CrossRef
EHF suppresses cancer progression by inhibiting ETS1-mediated ZEB expression
Kaname Sakamoto, Kaori Endo, Kei Sakamoto, Kou Kayamori, Shogo Ehata, Jiro Ichikawa, Takashi Ando, Ryosuke Nakamura, Yujiro Kimura, Kunio Yoshizawa, Keisuke Masuyama, Tomoyuki Kawataki, Kunio Miyake, Hiroki Ishii, Tomonori Kawasaki, Keiji Miyazawa, Masao
Oncogenesis.2021;[Epub] CrossRef
Sequential chemotherapy regimen of induction with panitumumab and paclitaxel followed by radiotherapy and panitumumab in patients with locally advanced head and neck cancer unfit for platinum derivatives. The phase II, PANTERA/TTCC-2010-06 study
J. Martínez-Trufero, A. Lozano Borbalas, I. Pajares Bernad, M. Taberna Sanz, E. Ortega Izquierdo, B. Cirauqui Cirauqui, J. Rubió-Casadevall, M. Plana Serrahima, J.M. Ponce Ortega, I. Planas Toledano, J. Caballero, J. Marruecos Querol, L. Iglesias Docampo,
Clinical and Translational Oncology.2021; 23(8): 1666. CrossRef
Divergent Roles of Induction Chemotherapy in Patients with Unresectable Locally Advanced Head and Neck Squamous Cell Carcinoma: A Population-Based Matched Cohort Study
Meng-Che Hsieh, Tzer-Zen Hwang, Chih-Chun Wang, Chuan-Chien Yang, Ching-Feng Lien, Chien-Chung Wang, Yu-Chen Shih, Wei-Ching Liu, Kun-Ming Rau
SSRN Electronic Journal .2021;[Epub] CrossRef
Statin in combination with cisplatin makes favorable tumor-immune microenvironment for immunotherapy of head and neck squamous cell carcinoma
Minsu Kwon, Gi-Hoon Nam, Hanul Jung, Seong A Kim, Seohyun Kim, Yeonju Choi, Yoon Se Lee, Hyo Jung Cho, In-San Kim
Cancer Letters.2021; 522: 198. CrossRef
The Role of Genetic Pathways in the Development of Chemoradiation Resistance in Nasopharyngeal Carcinoma (NPC) Patients
Norhafiza Mat Lazim, Che Ismail Che Lah, Wan Khairunnisa Wan Juhari, Sarina Sulong, Bin Alwi Zilfalil, Baharudin Abdullah
Genes.2021; 12(11): 1835. CrossRef
Indian clinical practice consensus guidelines for the management of oropharyngeal cancer
Kumar Prabhash, Govind Babu, Pankaj Chaturvedi, Moni Kuriakose, Praveen Birur, AnilK Anand, Ashish Kaushal, Abhishek Mahajan, Judita Syiemlieh, Manish Singhal, Munish Gairola, Prakash Ramachandra, Sumit Goyal, Subashini John, Rohit Nayyar, VijayM Patil, V
Indian Journal of Cancer.2020; 57(5): 12. CrossRef
Locally advanced oral tongue cancer: Is organ preservation a safe option in resource-limited high-volume setting?
Muntazir Hussain, Muhammad Faisal, Muhammad Abu Bakar, Tahir Muhammad, Saman Qadeer, Sameen Mohtasham, Raza Hussain, Arif Jamshed
Annals of Maxillofacial Surgery.2020; 10(1): 158. CrossRef
Present and Future of De-intensification Strategies in the Treatment of Oropharyngeal Carcinoma
Armando De Virgilio, Andrea Costantino, Giuseppe Mercante, Gerardo Petruzzi, Daniela Sebastiani, Ciro Franzese, Marta Scorsetti, Raul Pellini, Luca Malvezzi, Giuseppe Spriano
Current Oncology Reports.2020;[Epub] CrossRef
Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13–01)
Yun-Gyoo Lee, Eun Joo Kang, Bhumsuk Keam, Jin-Hyuk Choi, Jin-Soo Kim, Keon Uk Park, Kyoung Eun Lee, Jung Hye Kwon, Keun-Wook Lee, Min Kyoung Kim, Hee Kyung Ahn, Seong Hoon Shin, Hye Ryun Kim, Sung-Bae Kim, Hwan Jung Yun
BMC Cancer.2020;[Epub] CrossRef
Local immune parameters as potential predictive markers in head and neck squamous cell carcinoma patients receiving induction chemotherapy and cetuximab
Andrea Ladányi, Bence Kapuvári, Eszter Papp, Erika Tóth, József Lövey, Katalin Horváth, Mária Gődény, Éva Remenár
Head & Neck.2019; 41(5): 1237. CrossRef
Das Ende der TPF-Induktion bei lokoregionär fortgeschrittenen HNO-Karzinomen? Induktionschemotherapie gefolgt von Cetuximab und Bestrahlung nicht effektiver als simultane Radiochemotherapie
R. M. Hermann, H. Christiansen
Strahlentherapie und Onkologie.2019; 195(3): 281. CrossRef
A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEx) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck (CSPOR HN01: ECRIPS Study)
Sadamoto Zenda, Yosuke Ota, Naomi Kiyota, Susumu Okano, Masato Fujii, Morimasa Kitamura, Shunji Takahashi, Tsutomu Ueda, Nobuya Monden, Takeharu Yamanaka, Makoto Tahara
Frontiers in Oncology.2019;[Epub] CrossRef
Induction chemotherapy in head and neck cancers: Results and controversies
Max Gau, Andy Karabajakian, Thibaut Reverdy, Eve-Marie Neidhardt, Jérôme Fayette
Oral Oncology.2019; 95: 164. CrossRef
CTX-Induktion gefolgt von Cetuximab und Bestrahlung nicht effektiver als simultane RCT
Hans Christiansen, Robert M. Hermann
InFo Hämatologie + Onkologie.2019; 22(7-8): 27. CrossRef
A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
Bhumsuk Keam, Keun-Wook Lee, Se-Hoon Lee, Jin-Soo Kim, Jin Ho Kim, Hong-Gyun Wu, Keun-Yong Eom, Suzy Kim, Soon-Hyun Ahn, Eun-Jae Chung, Seong Keun Kwon, Woo-Jin Jeong, Young Ho Jung, Ji-Won Kim, Dae Seog Heo
The Oncologist.2019; 24(6): 751. CrossRef
Platelet-lymphocyte and neutrophil-lymphocyte ratios
Yu-Hsi Liu, Yaoh-Shiang Lin
Journal of the Chinese Medical Association.2019; 82(11): 849. CrossRef
Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter rando
Ying Lu, Dagui Chen, Jinhui Liang, Jianquan Gao, Zhanxiong Luo, Rensheng Wang, Wenqi Liu, Changjie Huang, Xuejian Ning, Meilian Liu, Haixin Huang
BMC Cancer.2019;[Epub] CrossRef
SEOM clinical guidelines for the treatment of head and neck cancer (2017)
L. C. Iglesias Docampo, V. Arrazubi Arrula, N. Baste Rotllan, A. Carral Maseda, B. Cirauqui Cirauqui, Y. Escobar, J. J. Lambea Sorrosal, M. Pastor Borgoñón, A. Rueda, J. J. Cruz Hernández
Clinical and Translational Oncology.2018; 20(1): 75. CrossRef
Radiotherapy for locally advanced resectable T3–T4 laryngeal cancer—does laryngeal preservation strategy compromise survival?
Hideya Yamazaki, Gen Suzuki, Satoaki Nakamura, Shigeru Hirano, Ken Yoshida, Koji Konishi, Teruki Teshima, Kazuhiko Ogawa
Journal of Radiation Research.2018; 59(1): 77. CrossRef
Any place left for induction chemotherapy for locally advanced head and neck squamous cell carcinoma?
Mickaël Burgy, Julie Leblanc, Christian Borel
Anti-Cancer Drugs.2018; 29(4): 287. CrossRef
A retrospective study of treatment for curative synchronous double primary cancers of the head and neck and the esophagus
Tabito Okamoto, Chikatoshi Katada, Shouko Komori, Keishi Yamashita, Shunsuke Miyamoto, Koichi Kano, Yutomo Seino, Hiroshi Hosono, Hiroki Matsuba, Hiromitsu Moriya, Mitsuhiro Sugawara, Mizutomo Azuma, Hiromichi Ishiyama, Satoshi Tanabe, Kazushige Hayakawa,
Auris Nasus Larynx.2018; 45(5): 1053. CrossRef
5-Fluorouracil induces inflammation and oxidative stress in the major salivary glands affecting salivary flow and saliva composition
Luana E. Bomfin, Cíntia M. Braga, Thais A. Oliveira, Conceição S. Martins, Danielle A. Foschetti, Ana A.Q.A. Santos, Deiziane V.S. Costa, Renata F.C. Leitão, Gerly A.C. Brito
Biochemical Pharmacology.2017;[Epub] CrossRef
Clinical and Histologic Predictive Factors of Response to Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma
Georgia Karpathiou, Jean-Baptiste Giroult, Fabien Forest, Pierre Fournel, Alessandra Monaya, Marios Froudarakis, Jean Marc Dumollard, Jean Michel Prades, Marie Gavid, Michel Peoc'h
American Journal of Clinical Pathology.2016; 146(5): 546. CrossRef

13,824 View
369 Download
37 Web of Science
40 Crossref

First
Prev
Page of 1
Next
Last

Search